Digestive system diseases

Medicinal products that are intended to improve digestion and metabolism, for example in Crohn’s disease, ulcerative colitis, short bowel syndrome or irritable bowel syndrome (IBS), are grouped by the G-BA into the category of diseases of the digestive system. Up until this time, 19 products have been assessed in 27 procedures. In the 43 subpopulations assessed by the G-BA, 0% have displayed a major, 0% a considerable and 17.6% a minor additional benefit in relation to the comparative therapy. A non-quantifiable additional benefit has been proved for a weighted 18.5% of the subpopulations. At the same time, no additional benefit was seen in 63.9% of the subpopulations, corresponding to 94% of the 1.05 million of the patients suitable for treatment with the assessed medicinal products.